Virology Research Journal

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1518-081136

Short Communication - Virology Research Journal (2023) Volume 7, Issue 1

Prevalence of chronic hepatitis B virus infection in patients with nucleotide analogue

The current available agents for the treatment of chronic hepatitis B (CHB) incorporate immunomodulatory operators, such as interferon-? and pegylated interferon-?, and verbal nucleoside/nucleotide analogs (NAs), counting lamivudine, adefovir, telbivudine, entecavir and tenofovir. The NAs work basically by restraining hepatitis B infection (HBV) DNA polymerase movement and hence stifle HBV replication. Verbal NAs have ended up the pillar of CHB treatment, primarily due to their significant viral suppressive impacts conjointly due in portion to the ease of single every day dosing and need of noteworthy side impacts. One major disadvantage of NA treatment is the advancement of sedate resistance transformations with long-term treatment. Lamivudine, the primary verbal NA endorsed for CHB patients, is related with tall rates of medicate resistance, with resultant virological backslide and biochemical flare. Luckily, more up to date and stronger NAs, such as entecavir and tenofovir, have exceptionally moo resistance rates, with strong and tough viral suppression. Author(s): Huang Niu

Abstract Full Text PDF

Get the App